246 related articles for article (PubMed ID: 16257863)
1. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study.
Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y
Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
3. Ultrastructure and chromogranin A immunogold labelling of ECL cell carcinoids.
Fossmark R; Martinsen TC; Qvigstad G; Bendheim MØ; Kopstad G; Kashima K; Waldum HL
APMIS; 2005; 113(7-8):506-12. PubMed ID: 16086820
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A
BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas].
Bohrer MH; Schmoll J
Verh Dtsch Ges Pathol; 1993; 77():107-10. PubMed ID: 7511265
[TBL] [Abstract][Full Text] [Related]
6. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
8. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
Nordin A; Wang W; Welén K; Damber JE
Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.
Mucci NR; Akdas G; Manely S; Rubin MA
Hum Pathol; 2000 Apr; 31(4):406-14. PubMed ID: 10821485
[TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo.
Palmer J; Ernst M; Hammacher A; Hertzog PJ
Prostate; 2005 Feb; 62(3):282-9. PubMed ID: 15389784
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
[TBL] [Abstract][Full Text] [Related]
13. Different patterns of chromogranin A and Leu-7 (CD57) expression in gastrointestinal carcinoids: immunohistochemical and confocal laser scanning microscopy study.
Jirásek T; Hozák P; Mandys V
Neoplasma; 2003; 50(1):1-7. PubMed ID: 12687271
[TBL] [Abstract][Full Text] [Related]
14. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker".
Abrahamsson PA; Falkmer S; Fält K; Grimelius L
Pathol Res Pract; 1989 Sep; 185(3):373-80. PubMed ID: 2813190
[TBL] [Abstract][Full Text] [Related]
15. Neoplastic endocrine cells in prostatic carcinoma: a case report with immunocytochemical and electron microscopic findings.
Watanabe K; Hoshi N; Hiraki H; Yamaki T; Tsu-Ura Y; Suzuki T
Fukushima J Med Sci; 1995 Jun; 41(1):51-60. PubMed ID: 8606042
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in human prostatic tumor models.
Noordzij MA; van Weerden WM; de Ridder CM; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Am J Pathol; 1996 Sep; 149(3):859-71. PubMed ID: 8780390
[TBL] [Abstract][Full Text] [Related]
17. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.
Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA
Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in non-small cell lung carcinomas.
Baldi A; Groger AM; Esposito V; Di Marino MP; Ferrara N; Baldi F
In Vivo; 2000; 14(1):109-14. PubMed ID: 10757067
[TBL] [Abstract][Full Text] [Related]
19. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin.
Gazdar AF; Helman LJ; Israel MA; Russell EK; Linnoila RI; Mulshine JL; Schuller HM; Park JG
Cancer Res; 1988 Jul; 48(14):4078-82. PubMed ID: 3383200
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis.
Shinji S; Naito Z; Ishiwata T; Tanaka N; Furukawa K; Suzuki H; Seya T; Kan H; Tsuruta H; Matsumoto S; Matsuda A; Teranishi N; Ohaki Y; Tajiri T
Int J Oncol; 2006 Aug; 29(2):357-64. PubMed ID: 16820877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
